Based on a long view of profit potential, a number of drug stocks trade at lower valuations than...
Based on a long view of profit potential, a number of drug stocks trade at lower valuations than peers, SmartMoney says. After weeding out firms facing major patent issues in coming years, six winners should emerge: Glaxo (GSK +0.4%), Roche (RHHBY.PK -0.9%), Pfizer (PFE -1.9%), Sanofi (SNY -0.7%), Merck (MRK +0.8%), Novartis (NVS +0.3%).
From other sites
at CNBC.com (May 28, 2015)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (May 6, 2015)
Video at CNBC.com (Jan 23, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs